Cargando…

Osteopontin, a bridge links osteoarthritis and osteoporosis

Osteoarthritis (OA) is the most prevalent joint disease characterized by degradation of articular cartilage, inflammation, and changes in periarticular and subchondral bone of joints. Osteoporosis (OP) is another systemic skeletal disease characterized by low bone mass and bone mineral density (BMD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Rui-Jun, Li, Yu-Sheng, Zhang, Fang-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649917/
https://www.ncbi.nlm.nih.gov/pubmed/36387862
http://dx.doi.org/10.3389/fendo.2022.1012508
_version_ 1784827891579617280
author Bai, Rui-Jun
Li, Yu-Sheng
Zhang, Fang-Jie
author_facet Bai, Rui-Jun
Li, Yu-Sheng
Zhang, Fang-Jie
author_sort Bai, Rui-Jun
collection PubMed
description Osteoarthritis (OA) is the most prevalent joint disease characterized by degradation of articular cartilage, inflammation, and changes in periarticular and subchondral bone of joints. Osteoporosis (OP) is another systemic skeletal disease characterized by low bone mass and bone mineral density (BMD) accompanied by microarchitectural deterioration in bone tissue and increased bone fragility and fracture risk. Both OA and OP are mainly affected on the elderly people. Recent studies have shown that osteopontin (OPN) plays a vital role in bone metabolism and homeostasis. OPN involves these biological activities through participating in the proliferation, migration, differentiation, and adhesion of several bone-related cells, including chondrocytes, synoviocytes, osteoclasts, osteoblasts, and marrow mesenchymal stem cells (MSCs). OPN has been demonstrated to be closely related to the occurrence and development of many bone-related diseases, such as OA and OP. This review summarizes the role of OPN in regulating inflammation activity and bone metabolism in OA and OP. Furthermore, some drugs that targeted OPN to treat OA and OP are also summarized in the review. However, the complex mechanism of OPN in regulating OA and OP is not fully elucidated, which drives us to explore the depth effect of OPN on these two bone diseases.
format Online
Article
Text
id pubmed-9649917
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96499172022-11-15 Osteopontin, a bridge links osteoarthritis and osteoporosis Bai, Rui-Jun Li, Yu-Sheng Zhang, Fang-Jie Front Endocrinol (Lausanne) Endocrinology Osteoarthritis (OA) is the most prevalent joint disease characterized by degradation of articular cartilage, inflammation, and changes in periarticular and subchondral bone of joints. Osteoporosis (OP) is another systemic skeletal disease characterized by low bone mass and bone mineral density (BMD) accompanied by microarchitectural deterioration in bone tissue and increased bone fragility and fracture risk. Both OA and OP are mainly affected on the elderly people. Recent studies have shown that osteopontin (OPN) plays a vital role in bone metabolism and homeostasis. OPN involves these biological activities through participating in the proliferation, migration, differentiation, and adhesion of several bone-related cells, including chondrocytes, synoviocytes, osteoclasts, osteoblasts, and marrow mesenchymal stem cells (MSCs). OPN has been demonstrated to be closely related to the occurrence and development of many bone-related diseases, such as OA and OP. This review summarizes the role of OPN in regulating inflammation activity and bone metabolism in OA and OP. Furthermore, some drugs that targeted OPN to treat OA and OP are also summarized in the review. However, the complex mechanism of OPN in regulating OA and OP is not fully elucidated, which drives us to explore the depth effect of OPN on these two bone diseases. Frontiers Media S.A. 2022-10-28 /pmc/articles/PMC9649917/ /pubmed/36387862 http://dx.doi.org/10.3389/fendo.2022.1012508 Text en Copyright © 2022 Bai, Li and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Bai, Rui-Jun
Li, Yu-Sheng
Zhang, Fang-Jie
Osteopontin, a bridge links osteoarthritis and osteoporosis
title Osteopontin, a bridge links osteoarthritis and osteoporosis
title_full Osteopontin, a bridge links osteoarthritis and osteoporosis
title_fullStr Osteopontin, a bridge links osteoarthritis and osteoporosis
title_full_unstemmed Osteopontin, a bridge links osteoarthritis and osteoporosis
title_short Osteopontin, a bridge links osteoarthritis and osteoporosis
title_sort osteopontin, a bridge links osteoarthritis and osteoporosis
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649917/
https://www.ncbi.nlm.nih.gov/pubmed/36387862
http://dx.doi.org/10.3389/fendo.2022.1012508
work_keys_str_mv AT bairuijun osteopontinabridgelinksosteoarthritisandosteoporosis
AT liyusheng osteopontinabridgelinksosteoarthritisandosteoporosis
AT zhangfangjie osteopontinabridgelinksosteoarthritisandosteoporosis